Not exact matches
(One of Hempel's daughters suffered a stroke after ICV administration of
cyclodextrin, although not as part of the NIH trial; it was being
administered separately under a compassionate use protocol approved by the Food and Drug Administration.)
But in studies of mouse models of the disease,
cyclodextrins, even when
administered peripherally, have significantly impacted the neurological damage; it's not known how.
In the combined phase one / two clinical trial, 14 NPC patients who were ages 4 to 23 years and showing neurological symptoms were given
cyclodextrin,
administered into the spinal column once per month for 12 to 18 months.